Clinical Trial Update: Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating vinorelbine plus paclitaxel for metastatic prostate cancer refractory to hormone therapy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Vinorelbine (Vinorelbine)

Snippet

Sponsor: James Ahlgren | Conditions: Prostate Cancer | Phase 2 | Status: WITHDRAWN